56O A phase Ia/Ib study of the MDM2-p53 antagonist brigimadlin (BI 907828): Safety and efficacy in patients with dedifferentiated liposarcoma

Schöffski, P., Lorusso, P., Yamamoto, N., Reichardt, P., Schwartz, L., Dercle, L., Zhao, B., Chitalia, R., Montgomery, G., Hu, C., Landsteiner, H. T., Jayadeva, G., & Gounder, M. (2024). 56O A phase Ia/Ib study of the MDM2-p53 antagonist brigimadlin (BI 907828): Safety and efficacy in patients with dedifferentiated liposarcoma. ESMO Open, 9, 102446. https://doi.org/10.1016/j.esmoop.2024.102446
Authors:
Patrick Schöffski
Patricia LoRusso
Nobuyuki Yamamoto
Peter Reichardt
Lawrence H. Schwartz
Laurent Dercle
B. Zhao
Rhea Chitalia
Grant W. Montgomery
Chen Hu
H.T. Landsteiner
Girish Jayadeva
Murugesan Gounder
Affiliated Authors:
Laurent Dercle
Columbia Affiliation:
Subjects:
Sarcoma Research and Treatment (OpenAlex Topic)
Targeted Protein Degradation in Biomedical Research (OpenAlex Topic)
Lymphoid Neoplasms (OpenAlex Topic)
elink
Publication Type:
Article
Unique ID:
10.1016/j.esmoop.2024.102446
DOI:
10.1016/j.esmoop.2024.102446
Journal:
ESMO Open
Publication Date:
Data Source:
OpenAlex
Source Link:
View OpenAlex Record

Record Created: